Amwill Health Care Ltd

Amwill Health Care Ltd — Trading Window Closed from October 1, 2026 till 48 hours after the declaration of the unaudited half-year 2026 results for the period ending September 30, 2026

Investments in AIF units

• Approved to invest up to ₹1.50 crore each in Vivriti Vihaan Trust and Neo Income Plus Fund III.
• Funding from internal accruals; no related party transactions.
• Timing: investments to be made in the ensuing month(s).
• Rationale: supports long-term growth and financial/operational objectives.
• Compliance: disclosure under SEBI Listing Regulations; information to be placed on company website.
• Investment committee approvals: 25 September 2026 (following 8 August 2026 approval).
• Total potential investment across both schemes up to ₹3.00 crore.

MD re-appointments

• Tarun Gandhi, MD & KMP, re-appointed for five years (Jan 27, 2027–Jan 26, 2032); relative of Anand Gandhi.
• Anand Gandhi, MD & KMP, re-appointed for five years (Jan 27, 2027–Jan 26, 2032); relative of Tarun Gandhi.

AGM Details

• Date and time: 14 August 2026 at 01:00 PM IST via VC/OAVM.
• Mode: VC/OAVM; record date for e-voting: 08 August 2026.
• Total shareholders on record: 1,453.
• Attendance: 6 Promoter Group and 14 Public via video.
• Meeting duration: 01:00–01:27 PM.

Resolutions and outcomes

• Ordinary Resolution 1: Adopt Audited financial statements for year ended 31 March 2026 — Passed (100% assent).
• Ordinary Resolution 2: Declare Final Dividend of Rs 0.50 per share — Passed (100% assent).
• Ordinary Resolution 3: Re-appoint Sapna Parmar as Director (rotational) — Passed (100% assent).
• Special Resolution 4: Re-appoint Tarun Gandhi as Managing Director for five years — Passed (99.94% assent).
• Special Resolution 5: Appoint Anand Gandhi as MD for five-year term ending Jan 2032 — Passed (99.94% assent).

Director changes

• Sapna Parmar retires by rotation and is re-appointed as Director.
• Tarun Gandhi re-appointed as MD for five-year term from Jan 27, 2027 to Jan 26, 2032.
• Anand Gandhi appointed as Managing Director for five-year term from Jan 27, 2027 to Jan 27, 2032.

AGM Details

• AGM held on 14 August 2026 at 01:00 IST via VC/OAVM.
• Deemed venue: Registered Office, Bangalore.
• Quorum: 20 members present.
• Remote e-Voting window: Aug 11–13, 2026; e-Voting during AGM.
• Scrutinizer appointed for e-voting; meeting concluded at 01:42 PM.

Resolutions

• Ordinary: Adopt Audited Financial Statements for year ended 31 March 2026.
• Ordinary: Declare Final Dividend on Equity Shares for FY ended 31 March 2026.
• Ordinary: Re-appoint Sapna Parmar (DIN 10198855) on rotation.
• Special: Re-appoint Tarun Gandhi as Managing Director.
• Special: Re-appoint Anand Gandhi as Managing Director.

Voting & Results

• Voting results will be disseminated separately to BSE and NSDL.
• No outcome details disclosed in this filing.

Dividend Details

• Final dividend amount per share not disclosed.

Directors & MD Appointments

• Sapna Parmar re-appointment on rotation.
• Tarun Gandhi re-appointed as MD.
• Anand Gandhi re-appointed as MD.

Auditors

• No change to statutory auditor; attendance noted.

Hybrid treasury investment framework

• Investment Committee approved a hybrid treasury framework using internal accruals on Aug 8, 2026.
• Debt-related investments (G-Secs, T-bills, government bonds, NCDs, CPs, other debt securities) cap ₹10 crore.
• Listed equity and IPO subscriptions cap ₹2 crore.
• Private credit funds, AIFs, structured debt cap ₹15 crore.
• Invoice discounting platforms and similar investments cap ₹3 crore.
• SIPs in mutual funds cap ₹3 crore (aggregate).
• Investment does not involve related party transactions.
• Compliance: SEBI Listing Regulations disclosures; available on company's website.

Tarun Gandhi – MD Re-appointment

• Re-appointed as MD & KMP for five years from Jan 27, 2027 to Jan 26, 2032.
• Subject to shareholders' approval via special resolution at the 9th AGM.
• Relation: Relative of Anand Gandhi.
• Brief profile: Commerce degree; 10+ years in financial management and business development.

Anand Gandhi – MD Re-appointment

• Re-appointed as MD & KMP for five years from Jan 27, 2027 to Jan 26, 2032.
• Subject to shareholders' approval via special resolution at the 9th AGM.
• Relation: Relative of Tarun Gandhi.
• Brief profile: Pharmacy degrees; 10+ years in brand placement, marketing, and dermatology.

Scrutinizer appointment

• Saurabh Talwar, CS, appointed Scrutinizer for remote and e-voting at AGM.
• Purpose: scrutinize remote e-Voting and e-Voting during eAGM.
• Designation: Company Secretary (COP No. 13338).

Appointments/Resignations

• Tarun Gandhi re-appointed MD & KMP for 5 years, Jan 27, 2027–Jan 26, 2032, subject to AGM approval.
• Anand Gandhi re-appointed MD & KMP for 5 years, Jan 27, 2027–Jan 26, 2032, subject to AGM approval.
• Directors Tarun Gandhi and Anand Gandhi are relatives.
• Both not debarred from holding director roles by SEBI or NSE authorities.

AGM Details

• 9th AGM scheduled for Aug 14, 2026 via VC/OAVM.
• Record date fixed as Aug 8, 2026 for AGM attendance and voting.
• Remote e-voting window Aug 11–13, 2026 via NSDL.
• Scrutinizer Mr. Saurabh Talwar appointed for AGM e-voting.
• Notice of AGM and Annual Report to be circulated electronically; available on company/BSE websites.

Financial Reporting & Communications

• FY2025-26 annual report including audited FS, Board's Report, MD&A, CSR to be laid before AGM.